Cognizin® is a patented form of citicoline with published RCT evidence for memory and attention. Complete guide to mechanism, clinical evidence and dose.
Cognizin® is a patented, stabilised form of citicoline (CDP-choline) with published randomised controlled trial evidence for cognitive support — specifically memory and attention. It supports acetylcholine synthesis and phosphatidylcholine production for brain cell membrane integrity. Clinical dose is 250-500mg daily.
Cognizin® is a patented form of citicoline (Cytidine Diphosphate-Choline) manufactured by Kyowa Hakko. It is a water-soluble compound that serves as a precursor to phosphatidylcholine — the primary phospholipid in brain cell membranes — and supports acetylcholine synthesis, the primary cognitive neurotransmitter.
McGlade et al. (2012) conducted a double-blind, placebo-controlled study of Cognizin® at 250mg and 500mg in healthy adult women. Both doses significantly improved attention and psychomotor speed versus placebo. A separate study confirmed improved memory performance in older adults.
Cognizin® appears in BrainPill® at a clinically relevant dose. Its presence distinguishes BrainPill® from nootropic products using generic citicoline or choline bitartrate — which have significantly different bioavailability profiles.